Drug Trial Radar · NCT07045909
Efficacy and Safety of Anitocabtagene Autoleucel in Participants With Newly Diagnosed Multiple Myeloma (GEM-AnitoFIRST)
Last checked: Nov 20, 2026Latest source record: Aug 1, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
Jun 30, 2025
Primary completion
Mar 31, 2028
Study completion Mar 31, 2030
Sponsor
- Lead sponsor
- PETHEMA FoundationAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jul 1, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn if anitocabtagene autoleucel following induction therapy works to treat adult participants with newly diagnosed multiple myeloma. The main objectives of this clinical trial are: * To determine the incidence and severity of all adverse events (AEs). * To determine the proportion of patients achieving undetectable minimal residual disease (uMRD) negative-CR rate (minimum 10 to -5) at 12 months (+/- 3 months) after enrollment. Participants will receive induction therapy with a quadruplet regimen including a proteasome inhibitor (Bortezomib \[V\]), immunomodulatory drug (Lenalidomide \[R\]), dexamethasone \[d\] and anti-CD38 monoclonal antibody (Daratumumab \[D\] or Isatuximab \[Isa\]) followed by anitocabtagene autoleucel. Participants in Cohorts A and B will receive lenalidomide maintenance therapy following infusion with anitocabtagene autoleucel.
Conditions
- De Novo Multiple Myeloma
- Anitocabtagene Autoleucel
Interventions
DaratumumabDrug
Daratumumab will be administered by subcutaneous (SC) injection.
IsatuximabDrug
Isatuximab will be administered IV.
BortezomibDrug
Bortezomib dose will be calculated using the patient's actual body surface area at baseline and will be administered by SC injection.
LenalidomideDrug
Lenalidomide will be administered by oral route (all cohorts at induction, and cohorts A and B at maintenance).
CyclophosphamideDrug
As part of lymphodepleting therapy before CAR-T manufacture, administered IV.
FludarabineDrug
As part of lymphodepleting therapy before CAR-T manufacture, administered IV
Anitocabtagene AutoleucelDrug
Single infusion IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and severity of all adverse events (AEs)Time frame: 3 years
- Undetectable minimal residual disease (uMRD) negative-CR rate (minimum 10-5) at 12 months (+/- 3 months) after enrollment.Time frame: 12 months
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
Hospital Germans Trias i Pujol (ICO BADALONA)
Badalona, Spain · Recruiting
H. Clinic de Barcelona
Barcelona, Spain · Recruiting
H. 12 de Octubre
Madrid, Spain · Recruiting
H. Ramón y Cajal
Madrid, Spain · Recruiting
Clinica Universidad de Navarra
Pamplona, Spain · Recruiting
Hospital Clinico Universitario Salamanca
Salamanca, Spain · Recruiting
H. Marqués de Valdecilla
Santander, Spain · Recruiting
C H Santiago de Compostela
Santiago de Compostela, Spain · Recruiting
Complejo Hosp. Regional Virgen del Rocío
Seville, Spain · Recruiting
Hospital Universitario y Politécnico La Fe de Valencia
Valencia, Spain · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.